BACKGROUND: Cystatin C (CC) has been proposed to play a role in atherosclerosis. We aimed to review the prognostic value of CC serum/plasma levels in patients with acute coronary syndromes (ACS). METHODS: Fifteen observational longitudinal studies were selected by Medline. RESULTS: Increased CC over threshold values ranging from 0.93 to 1.3 mg/L were prognostic for death (hazard ratio; HR: 2.04-3.6) and for the occurrence of any fatal and non-fatal cardiovascular events (HR: 1.7-9.6) for patients with either ACS only or coronary heart disease and prevalent ACS. Only one study showed an increased risk for future myocardial infarction (MI) in patients with marker levels higher than 1.0 mg/L. Three studies reported the risk associated with a change of one unit of CC for long-term death (HR ranging from 1.9 to 6.3) and for the composite end point of 1 year MI and death (HR 2.15). Some studies showed the additional prognostic value contributed from CC measurements to other markers and to conventional risk scores. CONCLUSION: Despite low to moderate evidence, there is a general agreement on the significant prognostic value of CC in ACS that might encourage further research focused on risk assessment for patients with MI.
BACKGROUND:Cystatin C (CC) has been proposed to play a role in atherosclerosis. We aimed to review the prognostic value of CC serum/plasma levels in patients with acute coronary syndromes (ACS). METHODS: Fifteen observational longitudinal studies were selected by Medline. RESULTS: Increased CC over threshold values ranging from 0.93 to 1.3 mg/L were prognostic for death (hazard ratio; HR: 2.04-3.6) and for the occurrence of any fatal and non-fatal cardiovascular events (HR: 1.7-9.6) for patients with either ACS only or coronary heart disease and prevalent ACS. Only one study showed an increased risk for future myocardial infarction (MI) in patients with marker levels higher than 1.0 mg/L. Three studies reported the risk associated with a change of one unit of CC for long-term death (HR ranging from 1.9 to 6.3) and for the composite end point of 1 year MI and death (HR 2.15). Some studies showed the additional prognostic value contributed from CC measurements to other markers and to conventional risk scores. CONCLUSION: Despite low to moderate evidence, there is a general agreement on the significant prognostic value of CC in ACS that might encourage further research focused on risk assessment for patients with MI.
Authors: Min Ji Shin; Sang Heon Song; Ihm Soo Kwak; Soo Bong Lee; Dong Won Lee; Eun Young Seong; Il Young Kim; Harin Rhee; Naria Lee Journal: Clin Exp Nephrol Date: 2012-01-26 Impact factor: 2.801
Authors: Johannes Arpegård; Alexander Viktorin; Zheng Chang; Ulf de Faire; Patrik K E Magnusson; Per Svensson Journal: J Am Heart Assoc Date: 2015-01-14 Impact factor: 5.501
Authors: Thor Ueland; Axel Åkerblom; Tatevik Ghukasyan; Annika E Michelsen; Pål Aukrust; Richard C Becker; Maria Bertilsson; Anders Himmelmann; Stefan K James; Agneta Siegbahn; Robert F Storey; Frederic Kontny; Lars Wallentin Journal: J Am Heart Assoc Date: 2018-01-12 Impact factor: 5.501